Jaime Mateus-Tique

Jaime Mateus-Tique

Auto-generated profile, based on publicly available information

Jaime Mateus-Tique

Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
ASAlfonso R. Sánchez-Paulete
Alfonso R. Sánchez-Paulete
JMJaime Mateus-Tique
Jaime Mateus-Tique
GMGurkan Mollaoglu
Gurkan Mollaoglu
SNSebastian R. Nielsen
Sebastian R. Nielsen
AMAdam Marks
Adam Marks
BBBrian D. Brown
Brian D. Brown
Tumor-associated macrophages (TAM) are one of the most abundant cell types in many solid tumors and typically exert protumor effects. This has led to an interest in macrophage-depleting agents for cancer therapy, but approaches developed to date have had limited success in clinical trials. Here, we report the development of a strategy for TAM depletion in mouse solid tumor models using chimeric antigen receptor (CAR) T cells targeting the macrophage marker F4/80 (F4.CAR-T). F4.CAR-T cells effectively killed macrophages in vitro and in vivo without toxicity. When injected into mice bearing orthotopic lung tumors, F4.CAR-T cells infiltrated tumor lesions and delayed tumor growth comparably with PD-1 blockade, and significantly extended mouse survival. Antitumor effects were mediated by F4.CAR-T–produced IFNγ, which promoted upregulation of MHC molecules on cancer cells and tumor-infiltrating myeloid cells. Notably, F4.CAR-T promoted expansion of endogenous CD8 T cells specific for tumor-associated antigen and led to immune editing of highly antigenic tumor cell clones. Antitumor impact was also observed in mouse models of ovarian and pancreatic cancer. These studies provide proof of principle to support CAR T-cell targeting of TAMs as a means to enhance antitumor immunity.

22 January 2026 in Cancer Cell
Verified
Journal Article
Closed access
JMJaime Mateus-Tique
Jaime Mateus-Tique
ALAshwitha Lakshmi
Ashwitha Lakshmi
BSBhavya Singh
Bhavya Singh
RIRhea Iyer
Rhea Iyer
ASAlfonso R. Sánchez-Paulete
Alfonso R. Sánchez-Paulete
BBBrian D. Brown
Brian D. Brown

24 November 2022 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
JMJaime Mateus-Tique
Jaime Mateus-Tique
BBBrian Brown
Brian Brown

4 April 2023
Verified
Other
Open access
ASAlfonso R. Sánchez-Paulete
Alfonso R. Sánchez-Paulete
JMJaime Mateus-Tique
Jaime Mateus-Tique
GMGurkan Mollaoglu
Gurkan Mollaoglu
SNSebastian R. Nielsen
Sebastian R. Nielsen
AMAdam Marks
Adam Marks
BBBrian D. Brown
Brian D. Brown
Tumor-associated macrophages (TAM) are one of the most abundant cell types in many solid tumors and typically exert protumor effects. This has led to an interest in macrophage-depleting agents for cancer therapy, but approaches developed to date have had limited success in clinical trials. Here, we report the development of a strategy for TAM depletion in mouse solid tumor models using chimeric antigen receptor (CAR) T cells targeting the macrophage marker F4/80 (F4.CAR-T). F4.CAR-T cells effectively killed macrophages in vitro and in vivo without toxicity. When injected into mice bearing orthotopic lung tumors, F4.CAR-T cells infiltrated tumor lesions and delayed tumor growth comparably with PD-1 blockade, and significantly extended mouse survival. Antitumor effects were mediated by F4.CAR-T–produced IFNγ, which promoted upregulation of MHC molecules on cancer cells and tumor-infiltrating myeloid cells. Notably, F4.CAR-T promoted expansion of endogenous CD8 T cells specific for tumor-associated antigen and led to immune editing of highly antigenic tumor cell clones. Antitumor impact was also observed in mouse models of ovarian and pancreatic cancer. These studies provide proof of principle to support CAR T-cell targeting of TAMs as a means to enhance antitumor immunity.

12 July 2024 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
NVNicolas Vabret
Nicolas Vabret
JMJaime Mateus-Tique
Jaime Mateus-Tique
HSHélène Salmon
Hélène Salmon
JMJérôme Martin
Jérôme Martin
VMVéronique Mateo
Véronique Mateo
MMMiriam Merad
Miriam Merad